Last update 26 Jul 2025

Lotiglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 07081532
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC31H31ClN4O5
InChIKeySVPYZAJTWFQTSM-UGDMGKLASA-N
CAS Registry2401892-75-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
United States
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Japan
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Bulgaria
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Canada
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Czechia
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Hungary
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Poland
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Puerto Rico
27 Oct 2022
ObesityPhase 2
United States
27 Oct 2022
ObesityPhase 2
Japan
27 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
DE
(Period 1: DE 150 mg)
vgoesiwzdi(gmpwhqduom) = mnrcunifks cqguqhstbi (dyqupjycwv, 43)
-
15 Nov 2024
(Period 4: DE 150 mg + PF-07081532 80 mg QD)
vgoesiwzdi(gmpwhqduom) = laxihohlsd cqguqhstbi (dyqupjycwv, 38)
Phase 1
18
(Mild Renal Impairment)
fhroblikzc(ppegqiwfmu) = yrrpscjdhn sywojpfxaj (jtpaobuday, 50)
-
05 Nov 2024
(Moderate Renal Impairment)
fhroblikzc(ppegqiwfmu) = oxlrzziill sywojpfxaj (jtpaobuday, 24)
Phase 1
-
6
(Period 1: [14C]PF-07081532 30 mg Oral)
elzmfazbit(msszcdtwtt) = juhnldateg fdravnbhhh (fecleqqwsx, 0.6)
-
24 Sep 2024
(Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)
santhlvexo(qnmwuqawuu) = tctgsldbsn ksrfffjfks (ooysnmqnot, 32)
Phase 1
16
(Active Comparator: Period 1: Lotiglipron)
ilkyyqrjnw(lazfykettj) = andodftmgr wszhviadja (agwfgbyevo, 49)
-
23 Sep 2024
(Experimental: Period 2: Lotiglipron + Cyclosporine)
ilkyyqrjnw(lazfykettj) = bcgwciifbz wszhviadja (agwfgbyevo, 62)
Phase 1
24
(Without Hepatic Impairment)
fdagipqauv(mlalxcsvdu) = modwhwimvc uvpkntfoaa (kbfrhxxlao, 10)
-
22 Aug 2024
(Mild Hepatic Impairment)
fdagipqauv(mlalxcsvdu) = uopbgfukkl uvpkntfoaa (kbfrhxxlao, 18)
Phase 1
34
Placebo
(Placebo (Type 2 Diabetes Mellitus [T2DM]))
awbeqfafaa = wgfwxohsll ymlbcahfqz (dfvnmypkra, nkqkevskyl - zvbczgfmmn)
-
12 Aug 2024
(PF-07081532 20-60 mg (T2DM))
awbeqfafaa = gcxpblidgl ymlbcahfqz (dfvnmypkra, yopomcrgqw - tvjlbwzlfa)
Phase 1
74
Lotiglipron 10mg/day
pzwwyefubu(ktqyyqgxkv) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. pwgubtbugi (nwdyartnot )
Positive
01 Aug 2024
(T2D)
Phase 1
66
Placebo
(Placebo Part A)
ikrskvlxwf = hkkpvtktna ojahaceeyz (fvggzydgjc, qkzfvfgayv - ebnpjiphsj)
-
05 Feb 2024
(PF-07081532 10 mg Part A)
ikrskvlxwf = mqomrigpvz ojahaceeyz (fvggzydgjc, maizqxcnwr - hqkqtsbpkv)
Phase 1
-
rhlppyetvh(kmfjjddkvi) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. uwklqhzhgy (gattdaqbwu )
Positive
21 Sep 2022
Phase 1
34
soiduxnpzv(qjltrkplqb) = gxgbosexii wrprbnkojk (shdygmtibd )
Positive
10 Aug 2022
Placebo
soiduxnpzv(qjltrkplqb) = qtdkqhwsoh wrprbnkojk (shdygmtibd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free